**SESN2 prevents the slow-to-fast myofiber shift in denervated atrophy via AMPK/PGC-1α pathway**

Xiaofan Yang1†, Pingping Xue2, Zhenyu Liu1, Wenqing Li3, Chuyan Li3 and Zhenbing Chen1*

---

**Abstract**

**Background:** Sestrin2 (SESN2), a stress-inducible protein, has been reported to protect against denervated muscle atrophy through unfolded protein response and mitophagy, while its role in myofiber type transition remains unknown.

**Methods:** A mouse sciatic nerve transection model was created to evaluate denervated muscle atrophy. Myofiber type transition was confirmed by western blot, fluorescence staining, ATP quantification, and metabolic enzyme activity analysis. Adeno-associated virus (AAV) was adopted to achieve SESN2 knockdown and overexpression in gastrocnemius. AMPK/PGC-1α signal was detected by western blot and activated with 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). C2C12 myotubes with rotenone treatment were adopted for in vitro experiments.

**Results:** SESN2 was found to be upregulated in denervated skeletal muscles and rotenone-treated C2C12 cells. Knockdown of SESN2 aggravated muscle atrophy and accelerated myofiber type transition from slow-twitch to fast-twitch. Moreover, AMPK/PGC-1α signaling was proven to be activated by SESN2 after denervation, which further induced the expression of hypoxia-inducible factor HIF2α. Exogenous activation of AMPK/PGC-1α signaling could counteract the addition of slow-to-fast myofiber shift caused by SESN2 knockdown and lead to the retainment of muscle mass after denervation.

**Conclusion:** Collectively, the present study indicates that SESN2 prevents myofiber type transition from slow-twitch to fast-twitch and preserves muscle mass in denervated atrophy via AMPK/PGC-1α signaling. These findings contribute to a better understanding of the pathogenesis of muscle atrophy and provide novel insights into the role of SESN2 in myofiber type transition.

**Keywords:** Denervation, Skeletal muscle atrophy, Myofiber type transition, SESN2, AMPK/PGC-1α

---

**Introduction**

Skeletal muscles primarily comprise long cylindric multinuclear cells, referred to as myofibers, which are responsible for muscular contractile activity [1]. Every skeletal muscle is composed of a heterogeneous collection of myofiber types with different...
physiologic adaptation in reaction to stimuli. The contraction of slow type-I myofibers is slow and fatigue-resistant, while fast myofibers contain a more efficient sarcoplasm reticulum and display faster contraction activity [2]. Every myofiber has a special molecule-level signature of myosin heavy-chain molecules (MHCs). Slow type-I myofibers predominantly express MYH7, but fast myofibers can be divided into three types: IIA (MYH2), IIX (MYH1), and IIB (MYH4). These fibers also differ in terms of oxidative/glycolytic metabolism, with type I and IIA fibers being more oxidative and type IIB fibers more glycolytic [3]. Muscle atrophy, characterized by a gradual decrease of myofiber transection area and protein levels, develops rapidly with remarkable weakness posterior to denervation and is related to the unsatisfactory prognoses of peripheral nerve damage [4]. Denervation-induced muscle atrophy is usually accompanied by a slow-to-fast shift in fiber type and MHC isoform profile, while the underlying mechanism has barely been elucidated [5].

The mutual transition of myofiber type is regulated by complex signaling pathways, in which the transcriptional co-activator PGC-1α, a key regulator of mitochondrial biogenesis, has been frequently reported [6]. During resistance and endurance exercise, the expression of PGC-1α achieves a remarkable increase, which induces the fast-to-slow myofiber shift and protects against muscle atrophy [7]. Furthermore, overexpression of PGC-1α in transgenic mice and pigs increased the proportion of red/oxidative type I fiber, accompanied by elevated levels of oxidative fiber markers such as MHC1, MHC2x, myoglobin, and Tnni1 [8]. As we know, PGC-1α is a downstream transcriptional regulator of AMP-activated protein kinase (AMPK, a key sensor of cellular metabolic and energy homeostasis), targeting AMPK to regulate myofiber type transition by various drugs is thus feasible [9, 10]. For example, naringin was reported to remarkably elevate the protein levels of slow MHC, myoglobin, and troponin I type I slow skeletal (troponin I-ss) and the activities of succinate dehydrogenase (SDH) and malate dehydrogenase (MDH), as well as reduce the fast MHC level and the activity of lactate dehydrogenase (LDH), accompanied by the activation of AMPK/PGC-1α signaling in mice and C2C12 myotubes [11].

Sestrins are stress-inducing proteins that prevent reactive oxygen species (ROS)- or endoplasmic reticulum stress (ERS)-related symptoms by inhibiting mTORC1 via the stimulation of AMPK [12–14]. Among three sestrin homologs (SESN1–3) in mammalian species, our team, in recent years, discovered that the expression level of SESN2 in skeletal muscle is increased upon denervation. Moreover, SESN2 was proven to mediate skeletal muscle accommodation to aberrant mitochondria function and ERS and was an endogenous attenuator of denervation-induced muscle atrophy [15]. However, whether SESN2 plays a role in denervation-induced slow-to-fast myofiber shift remains unclear. Thus, the purpose of this study was to further elucidate the relationship between SESN2 expression and myofiber type transition upon denervation. The results of this study will clarify a novel role and mechanism of SESN2 in denervated muscle atrophy.

Materials and methods
Animal procedures
Male 10-week-old C57BL/6 J mice, kept in a 24 h light/dark period environment, were provided by SPF (Beijing) Biotechnology Co., Ltd. Denervation was completed via
surgery on the right hind legs as delineated previously [16]. The mice were then randomly divided into four groups (six mice per group): sham operation group (control); denervation group; denervation + AAV-shSESN2 (adeno-associated virus, U6-MCS-CAG-EGFP; Genochem, China) group and denervation + AAV-SESN2 group (CMV-betaGlobin-MCS-SV40 PolyA, Genochem). The sequence of shSESN2 primers was 5'-GCG TCT TTG GCA TCA GAT ACG-3'. AAV9 injections of gastrocnemius (GAS) were completed 3 weeks in advance to construct SESN2 knockout or overexpression models. In particular, 10 µl of virus (1.0 × 10^{12} viral genomes (vg)/ml) were injected into each point around the gastrocnemius. To prevent the backflow of viral particles, the syringe was left in place for an extra 5 min after injection. Four to six injections were conducted on every limb. As for preparation of AMPK activation models, AICAR (an AMPK activator; MedChemExpress, USA, HY-13417) was administered to the mice via an intraperitoneal injection at a dose of 500 mg/kg once a day for 7 days prior to operation. An additional 7 days of AICAR treatment was performed until muscles were collected. Mice were euthanized by cervical dislocation at the indicated time, and GAS, extensor digitorum longus (EDL), and soleus (SOL) were removed, weighed, and frozen for the next experiments. For cervical dislocation, a trained person grasped the skin on the back of the neck by the thumb and forefinger and immediately pulled on the base of the tail in an opposite upward direction from the head. The immediate dislocation of the spinal column from the brain ensured death within a few seconds.

All animal experiments were completed as per the guidelines of the Chinese National Institutes of Health and obtained the approval of the Ethical Committee on Animal Experiments (Huazhong University of Science and Technology, no. 2021-S2789).

**Muscle mass measurements, H&E staining, and fiber diameter quantification**

Muscles (GAS, EDL, and SOL) of the denervated and control sides were collected and weighed at the proper temporal points. The wet weight ratio (muscular weight of the denervated side divided by the weight of the control side) was utilized to assess muscle atrophy.

For hematoxylin and eosin (H&E) staining, muscle samples were subjected to fixation in paraformaldehyde (4%) for 24 h, and afterwards subjected to dehydration and paraffin embedment. The 4-µm cross-cutting muscle sections were acquired before H&E staining (Bioyear, PRC) as per the instructions.

For quantitative analysis of fiber diameters, muscular transection was stained for wheat germ agglutinin (WGA) to visualize the fibers. ImageJ program was leveraged to quantify the minimum Feret’s diameter of myofibers stochastically selected within each group.

**Western blot**

The primary antibodies below were utilized: myosin heavy chain (MHC; R&D Systems, USA, MAB4470), slow MHC (Abcam, ab185967), fast MHC (Abcam, ab91506), MHC IIa (Abcam, ab124937), MHC IIb (Abcam, ab221149), myoglobin (Santa Cruz, USA, sc-393020), troponin I-ss (Santa Cruz, sc-514899), TOM20 (Abcam, UK, ab186735), TIM23 (Abcam, ab230253), SESN2 (Abcam, ab178518), AMPK (Cell Signaling Technology [CST], USA, 5831), phospho-AMPK (CST, 50081), PGC-1α (Abcam, ab106814),
HIF-2α (Abcam, ab109616), GAPDH (Protein Technology, PRC, 60004-1-Ig). The primary antibody dilution factors were 1:3000 (R&D Systems), 1:5000 (Protein Technology), or 1:1000 (Abcam and CST).

In short, the protein was abstracted via RIPA lysis buffering solution to which 1% protease suppressor was added (Roche, USA, 11206893001). The same quantity of protein (10–50 μg) was isolated via 10% SDS–PAGE, and afterwards moved onto nitrocellulose films (Merck Millipore, USA, Z358657). The films were subjected to blockade with 5% w/v BSA prior to cultivation with the first antibodies under 4 °C overnight. Subsequently, the films were cultivated with second antibodies conjugated with antirabbit or antimouse IgG (Abcam) for 60 min under ambient temperature and visualized via the Immobilon ECL matrix tool (Merck Millipore, WBKLS0050).

**Immunofluorescence**

Paraffin-embedded GAS underwent cross-sectional cuts, which were made into 4-μm sections as previously stated [16]. Following antigen retrieval, permeabilization, and goat serum blocking, primary antibody (mouse anti-slow MHC antibody and rabbit-anti-fast MHC antibody; Abcam) incubation was implemented at 4 °C. Next, samples were stained for 1 h using secondary Alexa Fluor 488-conjugated goat anti-mouse and Alexa Fluor 647-conjugated goat anti-rabbit IgG antibodies (Abcam, ab150113 and ab150079), followed by 5 min DAPI/PI (Sigma, USA, D9542) staining. The samples were then imaged with a fluorescence microscope. Similar processes were oriented with C2C12 cells.

**ATP level**

ATP contents in mouse GAS were identified via ATP analysis tool (Beyotime, China, S0026). Briefly, GAS tissue was homogenized in ATP assay lysis buffering solution, and the supernatant was harvested via centrifugation at 12,000g for 300 s under 4 °C and subjected to quantification via BCA analysis. Subsequently, 100 μl ATP identification reagent was supplemented into 100 μl supernatant, and the firefly luciferase (FFL) activity was identified and studied via luminescent spectrometric analysis (EnSpire, USA). The ATP content was normalized to cell protein level and presented as proportion (%) in contrast to the controls. Similar procedures were performed in C2C12 cells.

**Metabolic enzyme activity analysis**

The activities of LDH and SDH were identified via commercially available tools bought from Nanjing Jiancheng Biological Engineering Institution (China, A020-1-2 and A022-1-1) as per the supplier’s specification. Specific enzyme activity was presented as U/mg protein.

**Cell culture and transfection**

C2C12 cells were obtained from iCell Bioscience Inc. and cultivated in DMEM (Gibco, USA) including 10% FBS (Gibco), 100 units/mL penicillin, and 100 μg/mL streptomycin solution (Sangon Biotech, China) in 5% CO₂ at 37 °C in a cell culture incubator. Cells were differentiated into myotubes posterior to the cultivation with differentiation medium (2% horse serum in DMEM) for 1 week as delineated previously [11]. For
genetic knockout, three short interference RNAs for murine SESN2 (siSESN2) and negative controls (siNC) were synthesized by RiboBio Company (PRC). The transfection process was completed as per the specification of Lipofectamine 2000 (Invitrogen, USA, 11668019). Cells were collected at 48 h posterior to the transfection process for the subsequent assays. siRNAs with maximal suppressive effect were utilized for assays later on. The siRNA sequences are presented in Additional file 1: Table S1.

Detection of mitochondrial ROS level
Identification of mitochondrial ROS (mtROS) was completed via the fluorogenic stain MitoSOX Red (Thermo Fisher, USA, M36008), which was targeted to mitochondria in alive cells. In short, 5 mM stock solution and 5 μM work solution of MitoSOX were produced as per the supplier’s specification. Cells were cultivated in work solution for 600 s without light under 37 °C and afterwards cleaned three times in a warm buffering solution. The pictures of alive cells were collected via a confocal laser scan microscope. Finally, more than 30 cells in every group were chosen stochastically to produce the eventual outcomes.

Statistical analysis
Statistical analysis of three independent experiments with at least three technical repetitions was conducted using GraphPad Prism 9.0.0 (GraphPad, USA), and the statistical data were expressed as mean ± standard deviation. Differences were evaluated by one-way or two-way analysis of variance (ANOVA) with Tukey post-hoc test. P-value less than 0.05 was considered statistically significant.

Results
Denervation led to skeletal muscle atrophy and slow-to-fast myofiber shift
To reveal the development of denervation-induced muscle atrophy, a murine sciatic nerve cross-section model was constructed and diverse types of skeletal muscle were studied. As described previously [15], muscular mass of GAS (mixed-type muscle), extensor digitorum longus (EDL; fast-twitch muscles involving type IIb and IIx myofibers), and soleus (SOL; slow-twitch muscles involving type I and IIa myofibers) reduced quickly upon denervation. In this process, muscle atrophy exhibited a representative two-phase characteristic with rapid weight loss (approximately 47%) in 14 days at the beginning and afterwards a slighter reduction (approximately 14%) in the following 14 days (Fig. 1A). As a vital structure protein in myofiber, MHC was identified via western blot and unveiled a similar change as reported previously (Fig. 1B). Later, H&E staining and WGA immunofluorescence were performed to quantify fiber diameter, revealing that denervation drove the myofibers to decrease with a progressively smaller diameter (Fig. 1C, D). Overall, skeletal muscles, irrespective of muscle type, atrophied quickly upon denervation.

Muscle atrophy is usually accompanied by myofiber type transition. As seen in Fig. 1E, a significant decrease of slow MHC, MHC IIa, myoglobin, and troponin I-ss was observed over time after denervation. In contrast, fast MHC and MHC IIb, meanwhile, increased dramatically. Immunofluorescence analysis indicated similar results, showing decreased percentage of slow oxidative fibers and increased percentage of fast glycolytic
fibers (Fig. 1F). As slow oxidative fibers contain more mitochondria than fast glycolytic fibers, such changes further led to reduced mitochondria number and ATP content (Fig. 1E, G, H). In addition, the activity of SDH and LDH, which were used as markers of oxidative and glycolytic capacities, was further detected. Obviously, denervation led to
attenuated SDH activity and enhanced LDH activity (Fig. 1I). Overall, denervation promoted myofiber type transition from slow-twitch to fast-twitch.

**SESN2 protected against muscle atrophy and myofiber type transition after denervation**

In this section, we explore the role of SESN2 in denervated muscle atrophy and myofiber type transition. Firstly, evident accumulation of SESN2 protein was identified in the 14 days at the beginning after denervation, before a progress decrease in the following 14 days (Fig. 2A). Given that the progression of muscle atrophy occurred mainly in the first 14 days in a coincidental manner, we speculated that SESN2 might participate in the process of muscle atrophy. Subsequently, SESN2 knockdown and overexpression models were produced to explore the participation of SESN2 in the muscle atrophy of denervated GAS. The expression of SESN2 was verified via western blot (Fig. 2B). GAS specimens were harvested 14 days after denervation. MHC expression and muscle mass evaluation unveiled that muscle atrophy was remarkably deteriorated posterior to SESN2 knockdown and was mildly reversed via SESN2 overexpression (not significant) (Fig. 2B, C). Analysis of fiber size revealed that the diameter of fibers decreased in denervated GAS and deteriorated by AAV-shSESN2 (Fig. 2D). Finally, the effect of SESN2 on myofiber type transition was explored. As seen in Fig. 2E, F, knockdown of SESN2 significantly accelerated the reduction of slow oxidative fiber and addition of fast glycolytic fiber. Overexpression of SESN2 in denervated GAS exerted no obvious effect on myofiber type transition. ATP content and enzyme activity analysis revealed a trend consistent with the above data (Fig. 2G, H). Together, the above results indicate that SESN2 protected against muscle atrophy and the slow-to-fast myofiber type shift upon denervation.

**Rotenone induced slow-to-fast fiber type shift in C2C12 myotubes**

To replicate the denervated condition in vitro, C2C12 cells were treated with a concentration gradient of rotenone (a mitochondrial electron transport chain complex I inhibitor). As expected, obvious accumulation of mtROS was observed in C2C12 cells treated with 100 nM or more rotenone (Fig. 3A). SESN2 was also induced by rotenone treatment (Fig. 3C). More importantly, rotenone treatment induced a significant reduction of slow MHC-positive myotubes and addition of fast MHC-positive myotubes (Fig. 3B). Analysis of protein expression, ATP content, and enzyme activity also revealed a consistent trend (Fig. 3C–E). Briefly, these data indicate that rotenone treatment could induce the slow-to-fast fiber type shift in C2C12 myotubes, which was similar to the in vivo denervation model. In the following experiments, 100 nM rotenone was adopted.

**Knockdown of SESN2 accelerated slow-to-fast fiber type shift in rotenone-treated C2C12 myotubes**

To further confirm the role of SESN2 in myofiber type transition in vitro, knockdown of SESN2 was achieved in rotenone-treated C2C12 cells. The inhibitory effect of siSESN2 was confirmed by western blot (Fig. 4A). Immunofluorescence analysis revealed that siSESN2 treatment significantly accelerated the rotenone-induced reduction of slow MHC-positive myotubes and addition of fast MHC-positive myotubes (Fig. 4B). The results of western blot indicated that knockdown of SESN2 further suppressed the expressions of slow oxidative fiber-related proteins (slow MHC, MHC Ila, myoglobin,
and troponin I-ss) and enhanced the expression of fast glycolytic fiber-related proteins (fast MHC, MHC IIb) (Fig. 4C). ATP content and enzyme activity detection displayed similar changes (Fig. 4D, E). These data prove that SESN2 was required to prevent slow-to-fast fiber type shift in rotenone-treated C2C12 myotubes.
Fig. 3 Rotenone induced slow-to-fast fiber type shift in C2C12 myotubes. A Mitochondrial ROS levels in C2C12 cells were detected by MitoSOX Red labeling. Scale bar, 10 μm. B Immunofluorescence analysis of slow and fast MHC. Scale bar, 50 μm. C Western blot analysis of slow and fast MHC. D, E Detection of relative ATP content and metabolic enzyme activity (LDH and SDH) in C2C12 myotubes. Data presented as mean ± SD. *P < 0.05 versus control (0 nM rotenone treatment). Rot rotenone.
Fig. 4 Knockdown of SESN2 accelerated slow-to-fast fiber type shift in rotenone-treated C2C12 myotubes.

A Western blot analysis confirming the effect of siSESN2.

B Immunofluorescence analysis of slow and fast MHC. Scale bar, 50 μm.

C Western blot analysis of proteins related to muscle fiber type.

D Detection of relative ATP content and metabolic enzyme activities (LDH and SDH) in C2C12 myotubes. Data presented as mean ± SD. *P < 0.05 versus siNC group. **P < 0.05 versus rotenone treatment group. Rot rotenone.
**SESN2 prevented slow-to-fast shift in rotenone-treated C2C12 myotubes via AMPK/PGC-1α pathway**

Given the vital role of AMPK/PGC-1α signaling in myofiber type transition, we wonder whether this signal was working downstream SESN2. As seen in Fig. 5A, rotenone treatment activated and induced expression of PGC-1α and HIF-2α, while knockdown of SESN2 reversed the above variation, confirming the regulatory effect of SESN2 on AMPK/PGC-1α signaling. To further clarify the role of AMPK/PGC-1α in myofiber type transition, C2C12 myotubes were pretreated with AICAR, an AMPK activator, before rotenone. It was seen that AICAR successfully activated AMPK and downstream PGC-1α and HIF-2α. Besides, AICAR treatment reversed the effect of rotenone, showing increased slow oxidative fiber-related proteins (slow MHC, MHC IIa, myoglobin, and troponin I-ss) and decreased fast glycolytic fiber-related proteins (fast MHC, MHC IIb) (Fig. 5B). Consistently, AICAR treatment reversed the rotenone-induced reduction of slow MHC-positive myotubes and addition of fast MHC-positive myotubes (Fig. 5C). This trend was further confirmed in the detection of ATP content and enzyme activity (Fig. 5D, E). To sum up, AMPK/PGC-1α signaling mediated the inhibitory effect of SESN2 on myofiber type transition.

**SESN2 activated AMPK/PGC-1α signaling in denervated muscle**

To investigate the relationship between SESN2 and AMPK/PGC-1α signaling in denervated atrophy, dynamic monitoring of protein content was performed. Similar to SESN2, AMPK was activated in the first 2 weeks after denervation, while the expression of PGC-1α and downstream HIF-2α reached a peak 1 week post-denervation and fell down rapidly afterwards (Fig. 6A). As AMPK/PGC-1α signaling is well documented in myofiber type transition, we speculated that this variation might be an endogenous protective response in the early stage of denervated muscle atrophy. Subsequently, GAS with SESN2 knockdown was isolated 1 week post-denervation for western blot. As seen in Fig. 6B, knockdown of SESN2 suppressed the activation of AMPK/PGC-1α in the early stage of denervation. Together, the above data prove that the AMPK/PGC-1α signaling was activated by SESN2 in denervated muscle.

**AMPK/PGC-1α signaling prevented slow-to-fast myofiber shift and protected against muscle atrophy upon denervation**

Here we wonder whether AMPK/PGC-1α signaling played a role in myofiber type transition. Western blot analysis of GAS isolated 1 week post-denervation indicated that knockdown of SESN2 significantly accelerated the decrease of slow oxidative fiber-related proteins (slow MHC, MHC IIa, myoglobin, and troponin I-ss) and increase of fast glycolytic fiber-related proteins (fast MHC, MHC IIb) induced by denervation, while the AICAR treatment made up for the lack of SESN2 (Fig. 7A). Consistently, knockdown of SESN2 led to a further reduction of slow oxidative fiber and addition of fast glycolytic fiber compared with the denervation + shNC group, while AICAR treatment reversed this trend induced by SESN2 knockdown (Fig. 7B). Detection of ATP content and enzyme activity also consolidated the effect of AICAR (Fig. 7C, D). It needs to be emphasized that the analysis of fiber type, ATP content, and enzyme activity was performed in GAS 2 weeks post-denervation given that muscle atrophy happens more
Fig. 5 SESN2 prevented slow-to-fast shift in rotenone-treated C2C12 myotubes via AMPK/PGC-1α pathway. 

A Western blot analysis of the regulatory effect of SESN2 on the activity of AMPK/PGC-1α signaling. 

B Western blot analysis of C2C12 myotubes treated with rotenone and AICAR (an AMPK activator) to confirm the role of AMPK/PGC-1α signaling in myofiber type transition. 

C Immunofluorescence analysis of slow and fast MHC. Scale bar, 50 μm. 

D, E Detection of relative ATP content and metabolic enzyme activity (LDH and SDH) in C2C12 myotubes. Data presented as mean ± SD. *P < 0.05 versus control or siNC group. #P < 0.05 versus rotenone treatment group. Rot rotenone, Con control
slowly than signal change. In short, these results demonstrate that AMPK/PGC-1α signaling attenuated the slow-to-fast fiber shift in denervated muscle. In addition to the role of AMPK/PGC-1α signaling in myofiber type transition, its effect on muscle atrophy was further clarified. It was obvious that knockdown of SESN2 further aggravated the denervation-induced weight loss, MHC degradation, and fiber diameter reduction. Interestingly, the addition of AICAR reversed all these effects and achieved a similar degree of atrophy to that of the denervation + shNC group (Fig. 7E–G). The above results indicate that AMPK/PGC-1α signaling protected against muscle atrophy upon denervation.

**Discussion**

According to previous research [17, 18], SESN2 is constantly triggered upon various stresses, and exhibits cytoprotection features via regulating the synthetic process of proteins, autophagic activity, and apoptosis. In our previous research, ERS and mitochondrial dysfunction were found in denervated muscle, while the endogenous expression of SESN2 in the early stage of denervation mediated unfolding protein response and mitophagy and ultimately alleviated muscle atrophy [15]. Given that myofiber type transition is a main feature of skeletal muscle atrophy, we wonder whether SESN2 was involved therein. As expected, the present study indicated that SESN2 was induced soon after denervation and subsequently activated the AMPK/PGC-1α signal, which was shown to prevent the slow-to-fast myofiber type shift in denervated muscle. This finding provides new insight into the function of SESN2 and extends our understanding of the process of myofiber type transition post-denervation.

In the past few years, myofiber type transition was observed and studied mainly in sports medicine, in which the PGC-1α signal was identified as the key regulator therein [19, 20]. As a versatile transcription co-activator, PGC-1α participates in various cell activities, including adaptive calorigenesis, fatty acid oxidation, gluconeogenesis, and mitochondrial biogenesis [21]. In skeletal muscle, PGC-1α is highly expressed in slow oxidation fibers rather than fast glycolytic
AMPK/PGC-1α signaling prevented slow-to-fast myofiber shift and protected against muscle atrophy upon denervation. A Western blot analysis confirmed the role of AMPK/PGC-1α signaling in myofiber type transition in denervated GAS. B Immunofluorescence analysis of fiber type composition in denervated GAS. Scale bar, 50 μm. C, D Relative ATP content and metabolic enzyme activities (LDH and SDH) in GAS with different treatment. E Appearance and wet weight ratio of GAS in different groups. F Western blot analysis confirmed the expressions of SESN2 and MHC. G Quantification of muscle fibers diameter by immunofluorescence staining of WGA. Scale bar, 50 μm. Data presented as mean ± SD. n = 6. *P < 0.05 versus denervation + shNC group. **P < 0.05 versus denervation + shSESN2 group. Den denervation.
fibers [22]. Numerous studies have confirmed a close association of muscular contraction activity with elevated expressing level of PGC-1α [23, 24]. Endurance exercise triggers the expression of PGC-1α mRNA and protein in rats and humans. Moreover, overexpression of PGC-1α can reinforce mitochondria biogenesis and facilitate the fast-to-slow myofiber transition in cultivated myoblasts and transgenic mice, which improves exercise performance [25]. However, the mechanism underlying myofiber fiber transition in denervated muscle was rarely reported. In the present research, a new role of PGC-1α was identified, where PGC-1α acted as an endogenous protective molecular against the slow-to-fast fiber shift and ultimately delayed the process of denervated muscle atrophy.

HIF-2α, as a member of the the Per–ARNT–Sim–bHLH family of transcription factors that regulate the cellular response to hypoxic conditions [26, 27], was also detected in the present study. According to previous research, HIF-2α acts as a key mediator of PGC-1α-dependent myofiber type transition, a process that is partially muscle selective [22]. In our research, a similar expression pattern of HIF-2α and PGC-1α was observed in denervated GAS and C2C12 myotubes. Moreover, indirect upregulation of PGC-1α and HIF-2α prevented the slow-to-fast myofiber type shift and protected against muscle atrophy. Consistent with previous research, we speculate that PGC-1α regulation of myofiber type transition in denervated muscle is HIF-2α dependent.

In the dynamic monitoring of AMPK/PGC-1α signaling, we noticed a mismatch in the expression of AMPK and downstream PGC-1α and HIF-2α, as described in Fig. 6A. Given that the SESN2–AMPK pathway has been widely reported to activate autophagy and suppress protein synthesis [28–30], we speculate that the regulation of SESN2–AMPK pathway on PGC-1α expression is biphasic, with a promotion effect at early stage and a suppression effect afterward. Of course, other mechanisms might also be involved in PGC-1α regulation therein and worthy of further research.

Considering that different muscles contain different fibers and may respond differently to denervation [31], it will be difficult to apply this new regulatory mechanism to muscles other than GAS. As reported in previous research, type I myofibers of rat soleus underwent remarkable atrophy upon denervation, while type I myofibers in EDL maintained basically the same size in the first 14 days posterior to sciatic nerve section. A similar diversity was identified in type IIA myofibers, which underwent evident atrophy in soleus but merely minor atrophy in EDL. In rat diaphragm, denervation was similarly discovered to induce atrophy of type IIX and IIB myofibers, and showed no variation in type IIA and hypertrophy of type I myofibers [32]. However, the present study was meaningful in that it identified potential molecular pathological mechanisms of myofiber type transition upon denervation, which were previously unknown and out of the spotlight.

Here we noticed that overexpression of SESN2 made no difference to myofiber type transition and muscle atrophy upon denervation. As stated before, we speculate that the induction of SESN2 in denervated gastrocnemius is an adaptive response that critically mediates skeletal muscle adaptation to denervation by preventing the slow-to-fast myofiber shift, and is not enough to counteract the denervation-induced muscle atrophy.

As the atrophy of skeletal muscle upon denervation is a complicated process, no suitable in vitro model has yet been designed capable of replicating such a denervated state. Given that mitochondrial dysfunction and ROS overproduction were considered as important
features of denervated atrophy [16, 33], C2C12 cells with rotenone treatment were adopted in the present research and achieved similar characteristics (evidenced by increased accumulation of ROS and obvious trend of slow-to-fast fiber shift). In addition, only male mice were adopted in this research in order to avoid the potential influence of biological sex on myofiber type and muscle atrophy. Considering that the skeletal muscle kinetics and fiber type composition was quite different in male and female mice [34], the process of muscle atrophy in female mice requires further study.

Conclusions
The present research revealed a new role of SESN2 in denervated muscle atrophy, where SESN2 activated the AMPK/PGC-1α signal at an early stage of denervation and prevented the slow-to-fast myofiber shift. These findings expand our understanding of SESN2 in muscle atrophy, and provide potential regulatory targets for myofiber type transition.

Abbreviations
SESN2: Sestrin2
MHC: Myosin heavy chain
AMPK: AMP-activated protein kinase
Troponin I-slow: Troponin I type I slow skeletal
SDH: Succinate dehydrogenase
LDH: Lactate dehydrogenase
ROS: Reactive oxygen species
ERS: Endoplasmic reticulum stress
GAS: Gastrocnemius
EDL: Extensor digitorum longus
SOL: Soleus
WGA: Wheat germ agglutinin

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s11658-022-00367-z.

Additional file 1: Table S1. The sequences of siRNAs.

Acknowledgements
Not applicable.

Author contributions
Acquisition of data: X.Y. and P.X.; analysis and interpretation of data: Z.L.; drafting of the manuscript: X.Y.; critical revision of the manuscript: W.L. and C.L.; study concept and design: Z.C. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (grant number 82101473), Natural Science Foundation of Hubei Province (grant number 2021CFCB106), and Clinical Research Fund of Wu Jieping Medical Foundation (grant number 320.6750.2021-04-70).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All animal experiments were completed as per the guidelines of the Chinese National Institutes of Health and obtained the approval of the Ethical Committee on Animal Experiments (Huazhong University of Science and Technology, no. 2021-52789).

Consent for publication
All the coauthors consent to publishing the paper in Cellular & Molecular Biology Letters.
Competing interests
The authors declare that they have no competing interests.

Received: 7 April 2022   Accepted: 19 July 2022
Published online: 09 August 2022

References
1. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev. 2011;91:1447–531.
2. Zierath JR, Hawley JA. Skeletal muscle fiber type: influence on contractile and metabolic properties. Plos Biol. 2004;2:e348.
3. Liu J, Liang X, Gan Z. Transcriptional regulatory circuits controlling muscle fiber type switching. Sci Chin Life Sci. 2015;58:321–7.
4. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704–8.
5. Wang Y, Pessin JE. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 2013;16:243–50.
6. Ruas JL, White JP, Kleiner S, Brannan KT, Harrison BC, et al. A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell. 2012;151:1319–31.
7. Senoo N, Miyoshi N, Goto-Inoue N, Minami K, Yoshimura R, Morita A, et al. PGC-1alpha-mediated changes in phospholipid profiles of exercise-trained skeletal muscle. J Lipid Res. 2015;56:2286–96.
8. Zhang L, Zhou Y, Wu W, Hou L, Chen H, Zuo B, et al. Skeletal muscle-specific overexpression of PGC-1α induces fiber-type conversion through enhanced mitochondrial respiration and fatty acid oxidation in mice and pigs. Int J Biol Sci. 2017;13:1152–62.
9. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc Natl Acad Sci USA. 2007;104:12017–22.
10. Wen W, Chen X, Huang Z, Chen H, Luo Y, et al. Resveratrol regulates muscle fiber type conversion via miR-22-3p and AMPK/SIRT1/PGC-1α pathway. J Nutr Biochem. 2020;77:108297.
11. Xu Y, Huang Z, Chen X, Jia G, Zhao H, Liu G. Naringin induces skeletal muscle fiber type transformation via AMPK/PGC-1α signaling pathway in mice and C2C12 myotubes. Nutr Res. 2021;92:99–108.
12. Segales J, Perdiguerou E, Serrano AL, Sousa-Victor P, Ortel L, Jardi M, et al. Sestrin prevents atrophy of disused and aging muscles by integrating anabolic and catabolic signals. Nat Commun. 2020;11:189.
13. Haiderov A, Budanov AV. Sestrin family—the stem controlling healthy ageing. Mech Ageing Dev. 2020;192:111379.
14. Chen Y, Huang T, Yu Z, Yu Q, Wang Y, Hu J, et al. The functions and roles of sestrins in regulating human diseases. Cell Mol Biol Lett. 2022;27:2.
15. Yang X, Xue P, Yuan M, Xu X, Wang C, Li W, et al. SESN2 protects against denervated muscle atrophy through unfolded protein response and mitophagy. Cell Death Dis. 2021;12:805.
16. Yang X, Xue P, Chen H, Yuan M, Kang Y, Duscher D, et al. Denervation drives skeletal muscle atrophy and induces mitochondrial dysfunction, mitophagy and apoptosis via miR-142a-5p/MFN1 axis. Theranostics. 2020;10:1415–32.
17. Liu Y, Li M, Du X, Huang Z, Quan N, Sestrin 2, a potential star of antioxidant stress in cardiovascular diseases. Free Radic Biol Med. 2021;163:56–68.
18. Wu D, Zhang H, Wu Q, Li F, Wang Y, Li S, et al. Sestrin 2 protects against LPS-induced acute lung injury by inducing mitophagy in alveolar macrophages. Life Sci. 2021;267:118941.
19. Schnyder S, Handschin C. Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise. Bone. 2015;80:115–25.
20. Ferraro E, Giammarioli AM, Chiadotto S, Spolletini I, Rosano G. Exercise-induced skeletal muscle remodeling and metabolic adaptation: redox signaling and role of autophagy. Antioxid Redox Signal. 2014;21:154–76.
21. Rius-Perez S, Torres-Cuevas I, Millan I, Ortega AL, Perez S. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696.
22. Rasbach KA, Gupta RK, Ruas JL, Wu J, Naseeri E, Eastrall J, et al. PGC-1α regulates a HIF2α-dependent switch in skeletal muscle fiber types. Proc Natl Acad Sci USA. 2010;107:21866–71.
23. Carter HN, Pauly M, Tryon LD, Hood DA. Effect of contractile activity on PGC-1α transcription in young and aged skeletal muscle. J Appl Physiol. 1985;1988(124):1605–15.
24. Theilen NT, Kunkel GH, Tyagi SC. The role of exercise and TFAM in preventing skeletal muscle atrophy. J Cell Physiol. 2017;232:2348–58.
30. Park HW, Park H, Ro SH, Jang I, Semple IA, Kim DN, et al. Hepatoprotective role of Sestrin2 against chronic ER stress. Nat Commun. 2014;5:4233.
31. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol. 2013;45:2191–9.
32. Aravamudan B, Mantilla CB, Zhan WZ, Sieck GC. Denervation effects on myonuclear domain size of rat diaphragm fibers. J Appl Physiol. 1985;2006(100):1617–22.
33. Hyatt H, Deminice R, Yoshihara T, Powers SK. Mitochondrial dysfunction induces muscle atrophy during prolonged inactivity: a review of the causes and effects. Arch Biochem Biophys. 2019;662:49–60.
34. Haizlip KM, Harrison BC, Leinwand LA. Sex-based differences in skeletal muscle kinetics and fiber-type composition. Physiology (Bethesda). 2015;30(1):30–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.